Country
Full text data for US and EP
Status
Type
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC
No.
Publication Number
Title
Publication/Patent Number Publication/Patent Number
Publication date Publication date
Application number Application number
Filing date Filing date
Inventor Inventor
Assignee Assignee
IPC IPC
1
US20190010467A1
Publication/Patent Number: US20190010467A1
Publication date: 2019-01-10
Application number: 16/130,528
Filing date: 2018-09-13
Abstract: Provided is a method for preparing cultured cells or tissues for transplantation, comprising at least one of the following steps 1) and 2): 1) when the cultured cells or tissues do not express an HLA-C molecule of at least one HLA-C groups expressed in the receipient's HLA-C locus, forcing the expression of an HLA-C molecule of said HLA-C group in the cultured cells or tissues, or 2) when the cultured cells or tissues are negative or weakly positive for HLA-Bw4 while the recipient is positive for HLA-Bw4, forcing the expression of an HLA molecule of HLA-Bw4 group in the cultured cells or tissues. Provided is a method for preparing cultured cells or tissues for transplantation, comprising at least one of the following steps 1) and 2): 1) when the cultured cells or tissues do not express an HLA-C molecule of at least one HLA-C groups expressed in the receipient's HLA-C ...more ...less
2
US20190031849A1
Publication/Patent Number: US20190031849A1
Publication date: 2019-01-31
Application number: 16/072,812
Filing date: 2017-01-26
Abstract: A low-density gel product of the present disclosure has a coating layer on a surface thereof, the coating layer being composed of a polymer of a gas-phase polymerizable monomer. The low-density gel product of the present disclosure has an improved mechanical strength. The low-density gel product is, for example, an aerogel or xerogel. The low-density gel product can be, for example, in the form of a monolithic body such as a sheet or in the form of particles. The gas-phase polymerizable monomer is, for example, at least one selected from an olefin, styrene, a styrene derivative, (meth)acrylic acid, a (meth)acrylic acid ester, para-xylylene, and a para-xylylene derivative. A low-density gel product of the present disclosure has a coating layer on a surface thereof, the coating layer being composed of a polymer of a gas-phase polymerizable monomer. The low-density gel product of the present disclosure has an improved mechanical strength. The ...more ...less
3
US20190013890A1
Publication/Patent Number: US20190013890A1
Publication date: 2019-01-10
Application number: 16/066,107
Filing date: 2016-12-28
Abstract: A transmitter using a channel aggregation in which available channels existing in various frequency bands are bound and transmitted and using an Orthogonal Frequency Division Multiplexing (OFDM), an Orthogonal Frequency Division Multiple Access (OFDMA), or a system similar to them as a modulation system. One or a plurality of transmission units are provided in parallel, and one or a plurality of transmission processing units are provided in parallel. The transmission processing unit has an inverse fast Fourier transforming circuit or a discrete inverse Fourier transforming circuit, a GI and overlap margin (OM) insertion circuit, and a time-domain windowing processing unit. The time-domain windowing processing unit multiplies a universal time-domain window function in accordance with a spectrum mask and transport electric power which are required in each channel, thereby suppressing out-of-band radiation electric power every channel. A kind and a window transition duration of the time-domain window function can be arbitrarily set every channel. A transmitter using a channel aggregation in which available channels existing in various frequency bands are bound and transmitted and using an Orthogonal Frequency Division Multiplexing (OFDM), an Orthogonal Frequency Division Multiple Access (OFDMA), or a system similar to ...more ...less
4
US20190067910A1
Publication/Patent Number: US20190067910A1
Publication date: 2019-02-28
Application number: 16/080,528
Filing date: 2017-02-13
Abstract: A thermal radiation light source includes a laminated body including m quantum layers laminated where m is an integer of 2 or more, including an n-layer and a p-layer sandwiching the quantum layers from both sides in the laminating direction, the n-layer made of an n-type semiconductor and the p-layer made of a p-type semiconductor; a voltage applying unit for the m quantum layers is directly or indirectly connected to the n-layer and p-layer sandwiching each layer applying a voltage for moving to the n-layers or p-layers a charge; a voltage switching unit switches ON/OFF of application of the voltage to the m quantum layers; and a photonic crystal portion disposed in the laminated body or adjacent to the laminated body, so that lights of m wavelengths resonate, the lights of the m wavelengths generated in the m quantum layers corresponding to transition energy between subbands in the quantum layer. A thermal radiation light source includes a laminated body including m quantum layers laminated where m is an integer of 2 or more, including an n-layer and a p-layer sandwiching the quantum layers from both sides in the laminating direction, the n-layer made of an n-type ...more ...less
5
US20190071736A1
Publication/Patent Number: US20190071736A1
Publication date: 2019-03-07
Application number: 15/697,831
Filing date: 2017-09-07
Abstract: Provided is a method for continuously visualizing and accurately determining a living cellular state per se. Disclosed are: a vector comprising 5′- and 3′-end nucleic acid sequences for integration and a reporter gene sequence positioned between the 5′- and 3′-end nucleic acid sequences for integration; a gene introduction agent comprising a first vector and a second vector; a cell comprising the vector or the agent; and a method for determining a cellular state by using the cell. Provided is a method for continuously visualizing and accurately determining a living cellular state per se. Disclosed are: a vector comprising 5′- and 3′-end nucleic acid sequences for integration and a reporter gene sequence positioned between the 5′- and ...more ...less
6
US20190008860A1
Publication/Patent Number: US20190008860A1
Publication date: 2019-01-10
Application number: 16/066,946
Filing date: 2016-12-29
Abstract: The present invention provides a prophylactic or therapeutic agent for Alzheimer's disease (AD) containing a combination of two or more compounds selected from the group consisting of compounds shown by compound Nos. 1 to 130. Since these compounds are existing drugs that have already been confirmed actually for safety and pharmacokinetics in human, they can be a means for a pre-emptive treatment of people at risk of AD and in a stage before developing mild cognitive impairment (MCI). The present invention provides a prophylactic or therapeutic agent for Alzheimer's disease (AD) containing a combination of two or more compounds selected from the group consisting of compounds shown by compound Nos. 1 to 130. Since these compounds are existing drugs that have ...more ...less
7
US10233426B2
Publication/Patent Number: US10233426B2
Publication date: 2019-03-19
Application number: 15/314,409
Filing date: 2015-05-29
Abstract: The present invention provides a method for inducing cardiac differentiation of a pluripotent stem cell, which comprises the steps of (1) culturing a pluripotent stem cell in a medium containing a WNT signaling activator and a PKC activator and (2) culturing the cell after the step (1) in a medium containing a WNT signaling inhibitor, a Src inhibitor, and an EGFR inhibitor. The present invention provides a method for inducing cardiac differentiation of a pluripotent stem cell, which comprises the steps of (1) culturing a pluripotent stem cell in a medium containing a WNT signaling activator and a PKC activator and (2) culturing the cell after the ...more ...less
8
US10295528B2
Publication/Patent Number: US10295528B2
Publication date: 2019-05-21
Application number: 15/301,762
Filing date: 2015-04-07
Abstract: The present invention relates to a method for screening an inhibitor of ATP11C or CDC50A, comprising determining (a) exposure of phosphatidylserine on cell surface, (b) engulfment of cells by macrophages, or (c) cleavage of ATP11C by caspase. The present invention also relates to a method for inducing engulfment of cells by macrophages, comprising inhibiting ATP11C or CDC50A. The present invention relates to a method for screening an inhibitor of ATP11C or CDC50A, comprising determining (a) exposure of phosphatidylserine on cell surface, (b) engulfment of cells by macrophages, or (c) cleavage of ATP11C by caspase. The present invention also relates ...more ...less
9
US20190062246A1
Publication/Patent Number: US20190062246A1
Publication date: 2019-02-28
Application number: 16/078,288
Filing date: 2017-02-03
Abstract: In a production method of the present disclosure, a 1,1′-binaphthyl precursor derivative, an organic acid, and an iodinating or brominating agent are mixed. The 1,1′-binaphthyl precursor derivative has a 1,1′-binaphthyl skeleton and has an electron-donating group at the 2-position of the 1,1′-binaphthyl skeleton and at the 2′-position of the 1,1′-binaphthyl skeleton, and the electron-donating group contains an oxygen atom directly bonded to the skeleton. With the production method of the present disclosure, a 1,1′-binaphthyl derivative having a substituent introduced at the 8-position and/or 8′-position of the 1,1′-binaphthyl skeleton can be obtained. The 1,1′-binaphthyl derivative obtained by the production method of the present disclosure can be a compound further having a substituent introduced at at least one position selected from the 4-position, 4′-position, 5-position, 5′-position, 6-position, and 6′-position of the 1,1′-binaphthyl skeleton. In a production method of the present disclosure, a 1,1′-binaphthyl precursor derivative, an organic acid, and an iodinating or brominating agent are mixed. The 1,1′-binaphthyl precursor derivative has a 1,1′-binaphthyl skeleton and has an electron-donating ...more ...less
10
US10240126B2
Publication/Patent Number: US10240126B2
Publication date: 2019-03-26
Application number: 14/897,599
Filing date: 2014-06-11
Abstract: A method for producing hematopoietic stem cells and/or hematopoietic progenitor cells from pluripotent stem cells is described. The method includes a step of culturing pluripotent stem cells in the presence of IGF2. A method is described for selecting an induced pluripotent stem cell(s) having high capacity to differentiate into hematopoietic stem cells and/or hematopoietic progenitor cells, or into blood cells, based on the expression level(s) of one or more genes such as TRIM58, CTSF, FAM19A5, and TCERG1L genes, or on the DNA methylation state(s) of the TRIM58, CSMD1, and/or FAM19A5 gene(s). A method for producing hematopoietic stem cells and/or hematopoietic progenitor cells from pluripotent stem cells is described. The method includes a step of culturing pluripotent stem cells in the presence of IGF2. A method is described for selecting an induced pluripotent stem ...more ...less
11
US10196609B2
Publication/Patent Number: US10196609B2
Publication date: 2019-02-05
Application number: 14/772,991
Filing date: 2014-02-05
Abstract: The present invention provides a composition for promoting cardiac differentiation of a pluripotent stem cell containing an EGFR inhibitor. The present invention also provides a kit for promoting cardiac differentiation containing an EGFR inhibitor and a method for inducing cardiac differentiation of a pluripotent stem cell comprising culturing the pluripotent stem cell in a medium containing an EGFR inhibitor. The present invention provides a composition for promoting cardiac differentiation of a pluripotent stem cell containing an EGFR inhibitor. The present invention also provides a kit for promoting cardiac differentiation containing an EGFR inhibitor and a method for inducing ...more ...less